ClinicalTrials.gg

Program

Dual-target CAR-NK cells

Its studies are mostly in Glioblastoma · Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms, led by Beijing Biotech.

Furthest: phase 2, since Feb 14, 20265 company-led studies, 5 open or runningNext primary completion: Feb 14, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Biotech55 open or runningphase 2since Feb 14, 2026Feb 14, 2026Feb 14, 2027phase 2 · NCT07467863

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 14, 2026First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07467863 · 48 planned · China
  2. Mar 14, 2026Phase 1 study in GlioblastomaNCT07480941 · 36 planned · China
  3. Mar 20, 2026Phase 2 study in Breast NeoplasmsNCT07510802 · 60 planned · China
  4. Apr 18, 2026Phase 1 study in GliomaNCT07551336 · 36 planned · China
  5. Jun 6, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07641023 · 60 planned · China

Ahead

  1. Feb 14, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07467863
  2. Feb 18, 2027Primary completion: phase 1 study in GlioblastomaNCT07480941
  3. Mar 14, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07641023
  4. Mar 14, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT07510802

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07641023Carcinoma, Non-Small-Cell Lung · China2RecruitingMar 14, 202760
NCT07551336Glioma · China1RecruitingApr 14, 202736
NCT07510802Breast Neoplasms · China2RecruitingMar 14, 202760
NCT07480941Glioblastoma · China1RecruitingFeb 18, 202736
NCT07467863Carcinoma, Non-Small-Cell Lung · China2RecruitingFeb 14, 202748

How it is read

Names in the registry

  • “Dual-target CAR-NK cells”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.